NCT05409027View on ClinicalTrials.gov

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

March 10, 2022

Study Completion Date

February 7, 2024

Conditions
Type 2 Diabetes Mellitus in ObeseObesityType2Diabetes
Interventions
DRUG

SPI-62

SPI-62 is supplied as 1 mg tablets for oral dosing.

DRUG

Cortisone-d8

Cortisone-d8 is supplied as a 1 mcg/mL solution for infusion

Trial Locations (1)

91911

ProSciento, Chula Vista

Sponsors
All Listed Sponsors
lead

Sparrow Pharmaceuticals

INDUSTRY

NCT05409027 - A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62 | Biotech Hunter | Biotech Hunter